PROCEPT BioRobotics generated $76.4 million in Q4 2025 revenue, a 12% increase year-over-year but 19% below the $94.1 million consensus. The company reported a $0.53 loss per share versus a consensus loss of $0.32, and gross margin fell to 61% from 64% a year earlier due to lower consumables revenue and a one-time field action expense.

U.S. handpiece and consumable revenue rose 16% to $34.0 million while system revenue held flat at $27.6 million. The installed base grew 42% to 718 systems, procedures reached a record 12,200, and 65 new systems were sold. Management realigned the commercial team, launched a dedicated activation unit, reduced inventory and end-of-quarter incentives, and increased handpiece prices by 5%.

First-quarter 2026 sales are forecast at $79 million to $82 million, below a $92.65 million consensus, with procedures of 12,000–12,800. Full-year revenue guidance was lowered to $390 million–$410 million from $410 million–$430 million, offset by a $3,500 handpiece price and closer alignment of handpiece and procedure volumes.

Shares plunged 26% in premarket trading to a new 52-week low, trading roughly 22% below their 20-day SMA and 32.5% below their 100-day SMA. The RSI sits at 44.45, indicating neutral momentum, while key technical levels include support at $21.00 and resistance at $26.00.